查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553571

基因轉移技術市場規模、佔有率、趨勢分析報告：按模式、按應用、按方法、按地區、細分市場預測，2024-2030

Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (AAV, Lentivirus, Retrovirus), By Application (Gene Therapy, Cell Therapy), By Method (Ex-vivo, In-vivo), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

基因轉移技術市場的成長和趨勢

Grand View Research, Inc.最新報告顯示，到2030年，全球基因轉移技術市場規模預計將達到102.7億美元，2024年至2030年複合年成長率為11.4%。

病毒載體的技術進步、先進療法的不斷增加以及先進治療產品的監管核准數量不斷增加是市場的關鍵驅動力。

幾種用於遺傳改變的新工具已經被引入，使科學界更容易在基因組層面上揭示疾病的複雜性，從而導致新的基因轉移方法的出現。此外，正在研究開發臨床相關載體，包括病毒和非病毒載體，以先進的治療方法對抗癌症和阿茲海默症慢性疾病，從而刺激市場收益。

該領域增加的投資和融資以支持各種基因轉移方法的研究、開發和製造，進一步加速了收益成長。目前約 70% 的基因和細胞治療項目是基於病毒載體，導致生物遞送技術的有機收益成長。營運商正在進行大量投資，以擴大其病毒載體生產能力並滿足不斷成長的需求。

考慮到理化基因傳遞方法不斷擴大的商機，主要參與企業正在加緊努力擴大業務。例如，奈米粒子由於其可調節的形態和生物行為，已證明其作為臨床應用的有前途的載體的效率。此類新興市場的發展預計將在未來幾年加速該市場的收益成長。

基因轉移技術市場報告亮點

  • 生物基因轉殖技術因其高效性和特異性而在臨床應用中廣泛應用，並將在2023年佔據該領域最大的收益佔有率。
  • 由於危及生命的疾病的治療方法方案不斷擴大，加上最近 CAR-T 療法的成功，基因療法的開發將成為 2023 年市場上主要的產生收入應用。
  • 最近的 SARS-CoV-2 爆發也刺激了全球對基於病毒載體的疫苗研發的投資，以對抗該病毒，預計這將推動該領域的成長。
  • 體外由於其轉導效率高、免疫抗原性反應低等優點佔據了主要的銷售佔有率。
  • 然而，體內和體外在慢性疾病的治療方面都取得了臨床成功，這兩個領域都有望在未來幾年實現良好的成長。
  • 由於美國擁有大量的生技公司和有利的法規環境，北美在收益方面佔據全球市場的主導地位。
  • 同時，預計亞太地區在預測期內將以最快的速度成長。
  • 由於亞洲國家的工廠擴張和新基地建設，CDMO 和病毒載體的製造環境不斷變化，正在刺激該地區載體的採用。
  • 主要參與企業正在與治療開發商合作，以支持產品開發過程。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 全球基因轉殖技術市場的變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球基因轉殖技術市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 全球基因轉殖技術市場：依模式估算及趨勢分析

  • 細分儀表板
  • 全球基因轉殖技術市場：模式變異分析，百萬美元，2023 年和 2030 年
  • 生物
  • 化學
  • 身體的

第5章 全球基因轉殖技術市場：按應用、估算與趨勢分析

  • 細分儀表板
  • 全球基因轉殖技術市場：應用變異分析，百萬美元，2023 年和 2030 年
  • 基因治療
  • 細胞療法
  • 疫苗
  • 研究

第6章 全球基因轉殖技術市場：方法估算及趨勢分析

  • 細分儀表板
  • 全球基因轉殖技術市場：方法變異分析，百萬美元，2023 年和 2030 年
  • ex vivo
  • in vivo
  • in vitro

第7章 全球基因轉殖技術市場：區域估計與趨勢分析

  • 2023 年和 2030 年全球基因轉移技術市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Horizon Discovery Ltd.
    • OriGene Technologies, Inc.
    • Oxford Biomedica PLC
    • SignaGen Laboratories
    • Flash Therapeutics
    • Takara Bio Inc.
    • Bio-Rad Laboratories, Inc.
    • System Biosciences, LLC.
    • Promega Corporation.
    • F. Hoffmann-La Roche Ltd
    • SIRION BIOTECH GmbH
    • Catalent, Inc.
簡介目錄
Product Code: GVR-4-68039-291-1

Gene Delivery Technologies Market Growth & Trends:

The global gene delivery technologies market size is expected to reach USD 10.27 billion by 2030, expanding at a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.

Several novel tools are being introduced for genetic alterations that have facilitated the scientific community to delineate the disease intricacies at the genomic level, leading to the emergence of novel gene delivery approaches. Furthermore, ongoing research to develop clinically relevant vectors including viral and non-viral vectors to combat chronic illnesses such as cancer, Alzheimer's, and others through advanced therapies is spurring the market revenue.

An increase in investment and financing in the space to support the research, development, and manufacturing of various modes of gene transfer further accelerates the revenue growth. Currently, around 70% of gene and cell therapy programs are based on viral vectors leading to organic revenue growth for biological delivery technologies. The operating players are investing significantly to scale up their viral vector manufacturing capability and meet the growing demand.

Considering growing opportunities in physio-chemical gene delivery approaches, key players are making focused efforts to boost their business presence. For instance, nanoparticles have proven their efficiency as promising vehicles for clinical usage owing to their tunable morphology, and biological behaviors. Such ongoing developments in the space are anticipated to accelerate revenue growth in this market in the coming years.

Gene Delivery Technologies Market Report Highlights:

  • The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment's largest revenue share in 2023
  • Gene therapy development is the key revenue-generating application in the 2023 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies
  • The recent pandemic of SARS-CoV-2 has also resulted in substantial global investments in R&D of viral vector-based vaccine to combat the virus, resulting in lucrative growth of this segment
  • The ex vivo method accounted for the major revenue share owing to its advantages such as high transduction efficiency and less immunogenic responses
  • However, both in vivo and ex vivo have shown clinical success in the treatment of chronic conditions, thus both segments are expected to witness lucrative growth in the coming years
  • Given the high number of biotech companies and a favorable regulatory environment in the U.S.; North America dominated the global market in terms of revenue
  • On the other hand, Asia Pacific is projected to grow at the fastest pace during the forecast period
  • Constantly evolving CDMO and viral vector manufacturing landscapes through plant expansions and new sites being built across the Asian countries is spurring the adoption of vectors in this region
  • The key players are engaged in collaboration with therapy developers to support their product development process

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Gene Delivery Technology Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Gene Delivery Technology Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Gene Delivery Technology Market: Mode Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Gene Delivery Technology Market: Mode Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Biological
    • 4.3.1. Biological Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Adenovirus
      • 4.3.2.1. Adenovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Retrovirus
      • 4.3.3.1. Retrovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. AAV
      • 4.3.4.1. AAV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Lentivirus
      • 4.3.5.1. Lentivirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Other Viruses
      • 4.3.6.1. Other Viruses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.7. Non-viral
      • 4.3.7.1. Non-viral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Chemical
    • 4.4.1. Chemical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Physical
    • 4.5.1. Physical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Gene Delivery Technology Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Gene Delivery Technology Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Gene Therapy
    • 5.3.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cell Therapy
    • 5.4.1. Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Vaccines
    • 5.5.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Research
    • 5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Gene Delivery Technology Market: Method Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Gene Delivery Technology Market: Method Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Ex vivo
    • 6.3.1. Ex vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. In vivo
    • 6.4.1. In vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. In vitro
    • 6.5.1. In vitro Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Gene Delivery Technology Market: Regional Estimates & Trend Analysis

  • 7.1. Global Gene Delivery Technology Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. QIAGEN
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Horizon Discovery Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. OriGene Technologies, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Oxford Biomedica PLC
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. SignaGen Laboratories
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Flash Therapeutics
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Takara Bio Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bio-Rad Laboratories, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. System Biosciences, LLC.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Promega Corporation.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. F. Hoffmann-La Roche Ltd
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. SIRION BIOTECH GmbH
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. Catalent, Inc.
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives